Full-Time

Operations Planner

Forge Biologics

Forge Biologics

201-500 employees

End-to-end manufacturing of AAV gene therapies

No salary listed

Columbus, OH, USA

Hybrid

Category
Biology & Biotech (2)
,
Required Skills
NetSuite
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Supply Chain, Operations Management, Life Sciences, or related field
  • 3+ years of experience in Operations Planning, Production Planning, or Materials Planning within biotech, pharmaceuticals, or GMP manufacturing facility
  • Strong understanding of GMP manufacturing environments and regulated production workflows
  • Comfortable in a fast paced and ever changing organization, where ambiguity of process exists
  • Experience planning complex, multi-step processes with long lead times and constrained capacity
  • Proficiency with ERP/MRP systems and advanced Excel or planning tools
  • Strong analytical, communication, and cross-functional collaboration skills
  • Committed to working in a team environment and supporting business in a respectful manner
Responsibilities
  • Develop and manage master production schedules (MPS) for gene therapy manufacturing and corresponding support activities.
  • Translate clinical and commercial demand forecasts into feasible manufacturing plans considering cleanroom capacity, equipment availability, labor, and campaign strategies.
  • Coordinate closely with Manufacturing, Quality, Supply Chain, MSAT, and Project Management to ensure schedule adherence and rapid issue resolution.
  • Monitor material readiness (critical raw materials, single-use components, vectors, etc) and proactively identify supply risks impacting production timelines.
  • Lead short- and long-range capacity planning to support pipeline growth, tech transfers, and scale-up activities in order to advise the Commercial team on available openings for new clients
  • Manage and communicate schedule changes driven by deviations, investigations, equipment downtime, resource limitations, or other applicable constraints.
  • Analyze planning performance metrics (e.g., schedule adherence, capacity utilization, on-time delivery, days of supply, inventory turns, etc) and drive continuous improvement initiatives.
  • Maintain accurate planning data within ERP/MRP systems (Netsuite, SmartSheets, PowerBI and customized excel tools).
  • Create process appropriate SOPs and Work Instructions, as it relates to planning accountabilities and update existing documentation, with a Continuous Improvement mindset.
  • Participate in S&OP / IBP processes, scenario modeling, and risk mitigation planning.
  • Listens attentively to internal departments and team members to relay information, responsibilities, and policies respectfully, effectively, and clearly
Desired Qualifications
  • Experience in cell and gene therapy, viral vectors (AAV, lentivirus), or similar manufacturing
  • Familiarity with patient-specific or small-batch manufacturing models
  • APICS certification (CPIM / CSCP) or similar
  • Experience with capacity modeling and scenario planning tools

Forge Biologics provides end-to-end development and manufacturing for gene therapies, using its gene therapy development engine to move ideas from the lab into scalable production. It focuses on AAV-based therapies and operates from Hearth, a large cGMP facility designed for manufacturing at scale. Revenue comes from offering manufacturing services to other companies and researchers, while also developing its own therapies for potential future products. Its goal is to become a leading, integrated manufacturing partner for gene therapies, helping rare genetic-disease programs reach the clinic and market.

Company Size

201-500

Company Stage

Acquired

Total Funding

$870M

Headquarters

Columbus, Ohio

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Eight ASGCT presentations in May 2025 highlight FUEL™ manufacturing innovations.
  • John Maslowski became CEO on October 1, 2024, driving commercial growth.
  • Partnerships with Affinia, Progeria Foundation, and Fractyl expand revenue pipelines.

What critics are saying

  • Ajinomoto diverts resources to larger CDMOs, diluting Forge's AAV focus within 12-24 months.
  • Hearth facility saturates from Progeria, Affinia, Fractyl partnerships, delaying production in 12-18 months.
  • Catalent's $16.5B acquisition floods AAV capacity, undercutting Forge pricing in 6-12 months.

What makes Forge Biologics unique

  • FUEL™ platform boosts AAV productivity, recovery, and quality using Ignition Cells™ and pEMBR™ 2.0.
  • 200,000 sq ft Hearth facility houses 20 cGMP suites with 20,000L bioreactor capacity.
  • End-to-end services span plasmid DNA, AAV manufacturing, and regulatory support.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Forge Biologics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

401(k) Company Match

Annual Bonus

Paid Parental Leave

Employee Assistance Program

Wellness Program

Onsite Fitness Facility

Company News

University of Pittsburgh
Apr 22nd, 2026
Innovation Institute Reports Record Number of Invention Disclosures, Despite Pandemic

From swimming devices to rare disease gene therapies, Pitt inventors never stop: The Innovation Institute reported a record 394 invention disclosures for last fiscal year, and Director Evan Facher says another robust year is ahead.

Contract Pharma
Mar 3rd, 2026
Progeria Research Foundation, Forge Biologics Enter Gene Therapy Mfg. Pact

Progeria Research Foundation, Forge Biologics enter gene therapy mfg. Pact. Forge Biologics will provide process development and manufacturing services to support gene therapy for ultrarare disease. March 3, 2026 Managing Editor, Contract Pharma The Progeria Research Foundation (PRF), a research organization developing treatments for Hutchinson-Gilford Progeria Syndrome, and Forge Biologics, a manufacturer of gene therapies, entered a manufacturing agreement to support the development and manufacture of SamPro-2, PRF's investigational gene therapy for adolescence with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. The manufacturing agreement leverages PRF's research-driven Progeria program with Forge's integrated gene therapy capabilities including process development, cGMP manufacturing, FUEL platform technologies, and regulatory consultation. Forge will provide manufacturing services for Investigative New Drug (IND)-enabling studies with SamPro-2, a gene therapy that uses adeno-associated virus (AAV), a commonly utilized delivery vehicle in gene therapy, to deliver a base editing approach designed to correct the single DNA base mutation in the lamin A gene that causes Progeria. "Behind every program like this are patients and families who have waited a long time for progress," said John Maslowski, president and chief executive officer of Forge Biologics. "The Progeria Research Foundation and its Gene Team have shown extraordinary dedication to advancing this science, and we are honored to partner with them. At Forge, we bring that same level of care, expertise, and technical rigor to our manufacturing work as we help advance this program for patients."

PharmaSource
May 15th, 2025
Forge Biologics Partners with Fractyl Health on AAV Manufacturing for Metabolic Gene Therapy

Forge Biologics partners with Fractyl Health on AAV manufacturing for metabolic gene therapy.

BioSpace
May 14th, 2025
Forge Biologics Announces Eight Presentations At The American Society Of Gene And Cell Therapy (Asgct) 28Th Annual Meeting

Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge’s FUEL™ AAV manufacturing platform, addressing the industry's need for more efficient manufacturingCOLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge’s FUEL™ platform and manufacturing innovations for gene therapies.“We’re proud to share Forge’s latest manufacturing advancements, underscoring our commitment to innovation as we help clients deliver transformative gene therapies to patients,” said John Maslowski, CEO and President of Forge. “Our experts will highlight how the FUEL™ AAV manufacturing platform, with its advanced technologies and product-specific optimizations, drives significant productivity gains. We’re also excited to present additional talks and posters on key analytical advances as we look toward a future of faster and more comprehensive analytics for product release.”SESSION PRESENTATIONSSponsored Symposium. Title: “Great Science Needs Innovative Manufacturing Technology”. Presenters:David Dismuke, Ph.D., Chief Technology Officer

BioProcess International
Nov 15th, 2024
Affinia and Forge team up to tackle cardiovascular diseases

Affinia Therapeutics announced that it is partnering with Forge Biologics to manufacture clinical trial material under GMP standards.